DigestRedComo funciona
Red
/
Empresas
Sc
No verificado

Scribe Therapeutics, Inc.

Sobre qué escribimos

BiotecnologíaCardiologíaFarmacéuticaIndustriaSalud

7 Comunicados de prensa

Ver todos los comunicados de prensa
18/06/2026
Mercado laboral
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Cardiología
Scribe Therapeutics Awarded More Than $25 Million From CIRM to Accelerate Additional CRISPR-Based Gene Editing Therapies for Cardiometabolic Disease Into Clinical Trials
Fuente
Scribe Therapeutics, Inc.
Editor
Business Wire
1.00
0
28/05/2026
Eventos
Industria
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Cardiología
Scribe Therapeutics Presents Late-Breaking Preclinical Data Supporting STX-1150, a Clinical-Stage Epigenetic Silencing Therapy Designed to Achieve Years of LDL-C Lowering After a Single Dose
Fuente
Scribe Therapeutics, Inc.
Editor
Business Wire
1.00
0
21/05/2026
Industria
Biotecnología
Salud
Medicina - Varios
Cardiología
Scribe Therapeutics Achieves Regulatory Clearance to Initiate First-in-Human Clinical Study of STX-1150 for LDL-C Reduction
Fuente
Scribe Therapeutics, Inc.
Editor
Business Wire
1.00
0
18/05/2026
Eventos
Industria
Cardiología
Biotecnología
Técnica
Salud
Farmacéutica
Ciencia
Software
Scribe Therapeutics Reports Preclinical Data at ASGCT 2026 Demonstrating Enhanced Potency and Specificity of Engineered CRISPR Technologies for Epigenetic Silencing and Gene Editing
Fuente
Scribe Therapeutics, Inc.
Editor
Business Wire
1.00
0
30/04/2026
Eventos
Salud
Biotecnología
Ciencia
Farmacéutica
Cardiología
Scribe Therapeutics to Highlight Engineered CRISPR Platform Advances and Lead Cardiometabolic Pipeline at ASGCT and EAS Congress 2026
Fuente
Scribe Therapeutics, Inc.
Editor
Business Wire
1.00
0
17/02/2026
Industria
Salud
Biotecnología
Farmacéutica
Cardiología
Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company
Fuente
Scribe Therapeutics, Inc.
Editor
Business Wire
1.00
0
20/01/2026
Ciencia
Cardiología
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Industria
Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction
Fuente
Scribe Therapeutics, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0